INTRODUCTION {#s1}
============

Cancer is still a global public health problem. According to the GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide \[[@R1]\]. In China, cancer has become the leading cause of death since 2010, with an estimate of 4292,000 new cancer cases and 2814,000 cancer deaths in 2015 \[[@R2]\]. As a multifactorial disease, it involves both genetic and environmental factors \[[@R3]\]. Accumulating evidence has indicated that inflammation plays a vital role in cancer development \[[@R4]--[@R6]\], and approximately 20% of all cancers are associated with chronic inflammation \[[@R7]\].

Interleukin-10 (IL-10) is an anti-inflammatory cytokine with both immunosuppressive and immunostimulatory activities \[[@R8]\]. Although the relationship between IL-10 and cancer has been extensively studied, the exact role of IL-10 in cancer is still elusive, since IL-10 have both cancer-promoting and -inhibiting properties \[[@R9], [@R10]\]. In view of these properties, we hypothesized that *IL-10* gene polymorphisms could influence cancer susceptibility.

The *IL-10* gene is located on chromosome 1q31-32, and is composed of five exons and four introns. *IL-10* gene promoter region is highly polymorphic, and three promoter single nucleotide polymorphisms (SNPs) such as -1082A/G (rs1800896), -819T/C (rs1800871) and -592A/C (rs1800872) have been reported to regulate IL-10 expression \[[@R11], [@R12]\] and alter the susceptibility to various types of cancers \[[@R13]--[@R16]\]. In the Chinese population, numerous case-control studies were performed to investigate the role of *IL-10* -1082A/G, -819T/C and -592A/C polymorphisms in cancer risk. However, the results remain inconclusive. Hence, we performed the present meta-analysis to investigate the association between three polymorphisms in *IL-10* gene and cancer susceptibility in the Chinese population.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

As shown in Figure [1](#F1){ref-type="fig"}, 1,596 published records were initially retrieved from PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI) and Wanfang database, and 14 more articles were identified by checking the references in the retrieved publications. After reviewing of the titles and abstracts, 1,535 articles were excluded, leaving only 75 articles for further assessment. Among them, we excluded one study \[[@R17]\] that was covered by another included publication \[[@R18]\], five case-only studies \[[@R19]--[@R23]\], five lacking detailed data for further analysis \[[@R24]--[@R28]\], and eleven that were considering the deviation from the Hardy-Weinberg equilibrium (HWE) \[[@R29]--[@R39]\]. Ultimately, 53 articles were included in the final meta-analysis. Of these 53 articles, 24 articles \[[@R40]--[@R63]\] include 26 studies examining *IL-10* -1082A/G polymorphism, 28 articles \[[@R18], [@R42], [@R43], [@R45], [@R47], [@R49], [@R52], [@R53], [@R57]-[@R61], [@R63]-[@R77]\] include 33 studies examining the -819T/C polymorphism, and 39 articles \[[@R18], [@R42], [@R43], [@R45], [@R47], [@R52], [@R53], [@R56]-[@R67], [@R69], [@R70], [@R73]-[@R76], [@R78]-[@R91]\] include 42 studies examining the -592A/C polymorphism (Table [1](#T1){ref-type="table"}). Of the 53 articles, two publications \[[@R18], [@R45]\] with three cancer types were considered as three studies and one publication \[[@R65]\] with two cancer types were also considered as two studies.

![Flow diagram of the study selection process](oncotarget-08-62382-g001){#F1}

###### Characteristics of studies included in the meta-analysis

  Surname \[ref\]             Year   Cancer type    Control source   Genotype method   Case   Control      MAF   HWE   Score                                         
  --------------------------- ------ -------------- ---------------- ----------------- ------ ------------ ----- ----- ------------ ----- ----- ----- ------ ------- ----
  **-1082A/G polymorphism**                                                                                                                                          
  Wu \[[@R40]\]               2002   Gastric        HB               Sequencing        135    14           1     150   208          11    1     220   0.03   0.057   6
  Heneghan \[[@R41]\] ^a^     2003   HCC            PB               Probe             86     12           0     98    90           7     0     97    0.04   0.712   10
  Shih \[[@R42]\]^a^          2005   Lung           HB               PCR-RFLP          115    39           0     154   194          11    0     205   0.03   0.693   8
  Wei \[[@R43]\]              2007   NPC            HB               PCR-RFLP          123    61           14    198   167          38    5     210   0.11   0.124   8
  Bai \[[@R44]\]^b^           2008   Gastric        HB               PCR-RFLP          89     22 (AG+GG)   111   104   7 (AG+GG)    111   NA    NA    7              
  Hsing \[[@R45]\]            2008   Gallbladder    PB               Taqman            231    23           1     255   624          99    7     730   0.08   0.173   12
  Hsing \[[@R45]\] ^a^        2008   EHBD           PB               Taqman            107    18           0     125   664          108   7     779   0.08   0.270   12
  Hsing \[[@R45]\]^a^         2008   AV             PB               Taqman            38     9            0     47    664          108   7     779   0.08   0.270   12
  Hao \[[@R46]\] ^b^          2009   Lung           PB               Taqman            36     7 (AG+GG)    43    46    6 (AG+GG)    52    NA    NA    7              
  Xiao \[[@R47]\] ^a^         2009   Gastric        HB               PCR-RFLP          176    41           3     220   593          31    0     624   0.03   0.525   9
  Kong \[[@R48]\]             2010   Breast         HB               PCR-RFLP          285    29           1     315   285          35    2     322   0.06   0.422   9
  Liu \[[@R49]\]              2010   HCC            HB               Taqman            131    35           4     170   160          24    3     187   0.08   0.075   5
  Niu \[[@R50]\] ^b^          2011   Prostate       PB               Sequencing        24     74 (AG+GG)   98    42    46 (AG+GG)   88    NA    NA    9              
  Wang \[[@R51]\]             2011   Cervical       PB               PCR-SSP           77     85           24    186   103          76    21    200   0.30   0.222   8
  He \[[@R52]\] ^a^           2012   Gastric        HB               PCR-RFLP          154    42           0     196   194          54    0     248   0.11   0.055   9
  Chang \[[@R53]\] ^a^        2013   HN             HB               Taqman            289    23           1     313   268          27    0     295   0.05   0.410   10
  Chen \[[@R54]\]             2013   Bladder        HB               AS-PCR            374    25           1     400   350          48    2     400   0.07   0.799   10
  Du \[[@R55]\]               2013   Esophageal     HB               PCR               95     20           3     118   103          15    1     119   0.07   0.587   8
  Pan \[[@R56]\]              2013   Gastric        HB               MassARRAY         263    41           4     308   264          41    3     308   0.08   0.329   9
  Cheng \[[@R57]\] ^a^        2015   NTCL           HB               PCR-LDR           101    24           0     125   237          60    3     300   0.11   0.710   10
  Fei \[[@R58]\]              2015   AML            HB               PCR-RFLP          75     70           22    167   159          134   35    328   0.31   0.398   8
  Hsu \[[@R59]\] ^a^          2015   Oral           HB               PCR-SSP           130    14           1     145   96           16    0     112   0.07   0.416   7
  Yang \[[@R60]\]             2015   Esophageal     HB               MassARRAY         41     106          99    246   46           204   242   492   0.30   0.751   9
  Bai \[[@R61]\]              2016   Cervical       HB               PCR-RFLP          74     75           16    165   80           72    13    165   0.30   0.563   8
  Cai \[[@R62]\] ^a^          2016   Colorectal     HB               MassARRAY         323    50           2     375   343          39    0     382   0.05   0.293   9
  Peng \[[@R63]\]             2016   HCC            PB               PCR-RFLP          83     74           16    173   96           74    12    182   0.27   0.653   10
  **-819T/C polymorphism**                                                                                                                                           
  Wu \[[@R64]\]               2003   Gastric        HB               Sequencing        88     105          27    220   127          83    20    230   0.27   0.231   9
  Savage \[[@R65]\]           2004   Gastric        PB               SBE               37     38           9     84    170          163   49    382   0.34   0.315   11
  Savage \[[@R65]\]           2004   Esophageal     PB               SBE               53     46           17    116   170          163   49    382   0.34   0.315   12
  Shih \[[@R42]\]             2005   Lung           HB               PCR-RFLP          66     58           30    154   104          86    15    205   0.28   0.627   8
  Wei \[[@R43]\]              2007   NPC            HB               PCR-RFLP          82     81           35    198   94           92    24    210   0.33   0.836   8
  Hsing \[[@R45]\]            2008   Gallbladder    PB               Taqman            122    92           23    237   311          335   82    728   0.34   0.564   12
  Hsing \[[@R45]\]            2008   EHBD           PB               Taqman            55     52           17    124   334          353   90    777   0.34   0.823   12
  Hsing \[[@R45]\]            2008   AV             PB               Taqman            20     6            21    47    334          353   90    777   0.34   0.823   12
  Yao \[[@R66]\]              2008   Oral           HB               PCR-RFLP          113    120          47    280   129          134   37    300   0.35   0.809   10
  Xiao \[[@R47]\]             2009   Gastric        HB               PCR-RFLP          100    100          20    220   272          283   69    624   0.34   0.719   9
  Liu \[[@R67]\]              2010   Prostate       HB               PCR-RFLP          120    108          34    262   132          110   28    270   0.31   0.477   10
  Liu \[[@R49]\]              2010   HCC            HB               Taqman            79     73           18    170   75           92    20    187   0.35   0.292   5
  Oh \[[@R18]\]               2010   Esophageal     PB               Taqman            90     79           27    196   179          158   42    379   0.32   0.426   13
  Oh \[[@R18]\]               2010   Gastric        PB               Taqman            81     87           20    188   179          158   42    379   0.32   0.426   13
  Oh \[[@R18]\]               2010   HCC            PB               Taqman            91     70           25    186   179          158   42    379   0.32   0.426   13
  Su \[[@R68]\]               2010   Gastric        HB               PCR-RFLP          18     21           4     43    51           43    6     100   0.28   0.433   6
  Bei \[[@R69]\]              2011   HCC            HB               Taqman            44     247          298   589   51           240   306   597   0.29   0.686   12
  Liu \[[@R70]\]              2011   Gastric        HB               PCR-RFLP          99     96           39    234   109          106   28    243   0.33   0.773   7
  He \[[@R52]\]               2012   Gastric        HB               PCR-RFLP          82     96           18    196   92           128   28    248   0.37   0.095   9
  He \[[@R71]\]               2012   Breast         HB               MALDI-TOF MS      177    141          29    347   229          223   44    496   0.31   0.322   10
  Yuan \[[@R72]\]             2012   Gastric        HB               MassARRAY         108    129          42    279   142          120   34    296   0.32   0.266   9
  Zeng \[[@R73]\]             2012   Gastric        PB               SBE               60     80           11    151   78           65    10    153   0.28   0.467   10
  Chang \[[@R53]\]            2013   HN             HB               Taqman            132    153          28    313   136          130   29    295   0.32   0.798   10
  Yao \[[@R74]\]              2013   AML            HB               PCR-RFLP          68     38           9     115   56           63    18    137   0.36   0.966   9
  Cheng \[[@R57]\]            2015   NTCL           HB               PCR-LDR           57     59           9     125   136          125   39    300   0.34   0.230   10
  Fei \[[@R58]\]              2015   AML            HB               PCR-RFLP          57     72           38    167   137          137   54    328   0.37   0.052   8
  Hsu \[[@R59]\]              2015   Oral           HB               PCR-SSP           33     101          11    145   53           51    8     112   0.30   0.363   7
  Yang \[[@R60]\]             2015   Esophageal     HB               MassARRAY         101    105          40    246   219          203   69    492   0.35   0.051   9
  Zhang \[[@R75]\]            2015   Lung           HB               PCR-RFLP          108    135          87    330   145          144   47    336   0.35   0.247   8
  Bai \[[@R61]\]              2016   Cervical       HB               PCR-RFLP          44     76           45    165   28           73    64    165   0.39   0.362   8
  Cui \[[@R76]\]              2016   Osteosarcoma   HB               PCR-RFLP          34     120          106   260   43           118   99    260   0.39   0.438   10
  Li \[[@R77]\]               2016   Gastric        HB               PCR-RFLP          36     83           38    157   36           127   85    248   0.40   0.300   6
  Peng \[[@R63]\]             2016   HCC            PB               PCR-RFLP          74     77           22    173   86           78    17    181   0.31   0.910   10
  **-592A/C polymorphism**                                                                                                                                           
  Wu \[[@R64]\]               2003   Gastric        HB               Sequencing        88     105          27    220   127          83    20    230   0.27   0.231   9
  Savage \[[@R65]\]           2004   Gastric        PB               SBE               9      39           36    84    49           166   171   386   0.34   0.383   11
  Savage \[[@R65]\]           2004   Esophageal     PB               SBE               17     51           51    119   49           166   171   386   0.34   0.383   12
  Shih \[[@R42]\]             2005   Lung           HB               PCR-RFLP          66     70           18    154   116          76    13    205   0.25   0.907   8
  Tseng \[[@R78]\]            2006   HCC            HB               MALDI-TOF MS      93     84           31    208   90           75    19    184   0.31   0.567   7
  Wei \[[@R43]\]              2007   NPC            HB               PCR-RFLP          82     81           35    198   94           92    24    210   0.33   0.836   8
  Hsing \[[@R45]\]            2008   Gallbladder    PB               Taqman            121    91           23    235   318          334   82    734   0.34   0.684   12
  Yao \[[@R66]\]              2008   Oral           HB               PCR-RFLP          113    120          47    280   129          134   37    300   0.35   0.809   10
  Xiao \[[@R47]\]             2009   Gastric        HB               PCR-RFLP          100    100          20    220   272          283   69    624   0.34   0.719   9
  Liu \[[@R67]\]              2010   Prostate       HB               PCR-RFLP          120    108          34    262   132          110   28    270   0.31   0.477   10
  Oh \[[@R18]\]               2010   Esophageal     PB               SNPlex            81     72           26    179   167          159   36    362   0.32   0.837   13
  Oh \[[@R18]\]               2010   Gastric        PB               SNPlex            77     81           20    178   167          159   36    362   0.32   0.837   13
  Oh \[[@R18]\]               2010   HCC            PB               SNPlex            82     68           19    169   167          159   36    362   0.32   0.837   13
  Xiong \[[@R79]\]            2010   Cervical       HB               PCR-RFLP          35     23           12    70    51           44    13    108   0.32   0.467   7
  Bei \[[@R69]\]              2011   HCC            HB               Taqman            42     248          299   589   49           244   304   597   0.29   0.997   12
  Liang \[[@R80]\]            2011   Lung           HB               PCR-RFLP          69     36           11    116   69           44    7     120   0.24   0.997   9
  Liu \[[@R70]\]              2011   Gastric        HB               PCR-RFLP          99     96           39    234   109          106   28    243   0.33   0.773   7
  Yu \[[@R81]\]               2011   Cervical       PB               PCR-RFLP          59     37           7     103   52           44    19    115   0.36   0.075   10
  He \[[@R52]\]               2012   Gastric        HB               PCR-RFLP          82     96           18    196   92           128   28    248   0.37   0.095   9
  Zeng \[[@R73]\]             2012   Gastric        PB               SBE               59     77           15    151   80           66    7     153   0.26   0.148   10
  Zhang \[[@R82]\]            2012   NHL            PB               Taqman            226    228          60    514   269          235   53    557   0.31   0.872   14
  Chang \[[@R53]\]            2013   HN             HB               Taqman            134    152          27    313   137          129   29    295   0.32   0.864   10
  Pan \[[@R56]\]              2013   Gastric        HB               MassARRAY         144    128          36    308   142          135   31    308   0.32   0.896   9
  Sun \[[@R83]\]              2013   Esophageal     HB               SNPscan           162    163          31    356   191          141   33    365   0.28   0.347   10
  Tsai \[[@R84]\]             2013   NPC            HB               PCR-RFLP          93     66           17    176   261          205   56    522   0.30   0.103   9
  Yao \[[@R74]\]              2013   AML            HB               PCR-RFLP          68     38           9     115   56           63    18    137   0.36   0.966   9
  Bei \[[@R85]\]              2014   HCC            HB               Taqman            356    312          52    720   392          313   79    784   0.30   0.160   11
  Hsia \[[@R86]\]             2014   Lung           HB               PCR-RFLP          173    145          40    358   368          277   71    716   0.29   0.080   12
  Kuo \[[@R87]\]              2014   Gastric        HB               PCR-RFLP          186    134          38    358   180          141   37    358   0.30   0.235   9
  Yu \[[@R88]\]               2014   Colorectal     PB               PCR-RFLP          153    114          31    298   118          135   38    291   0.36   0.950   13
  Cheng \[[@R57]\]            2015   NTCL           HB               PCR-LDR           57     59           9     125   138          124   38    300   0.33   0.225   10
  Fei \[[@R58]\]              2015   AML            HB               PCR-RFLP          54     74           39    167   126          142   59    328   0.40   0.091   8
  Hsu \[[@R59]\]              2015   Oral           HB               PCR-SSP           33     101          11    145   53           51    8     112   0.30   0.363   7
  Yang \[[@R60]\]             2015   Esophageal     HB               MassARRAY         85     116          45    246   185          228   79    492   0.39   0.534   9
  Yin \[[@R89]\]              2015   Gastric        HB               SNPscan           112    96           20    228   235          184   42    461   0.29   0.491   10
  Zhang \[[@R75]\]            2015   Lung           HB               PCR-RFLP          64     156          110   330   85           176   75    336   0.49   0.374   8
  Bai \[[@R61]\]              2016   Cervical       HB               PCR-RFLP          63     82           20    165   70           80    15    165   0.33   0.243   8
  Cai \[[@R62]\]              2016   Colorectal     HB               MassARRAY         221    128          26    375   184          158   40    382   0.31   0.485   9
  Chang \[[@R90]\]            2016   RCC            HB               PCR-RFLP          61     27           4     92    371          185   24    580   0.20   0.877   9
  Cui \[[@R76]\]              2016   Osteosarcoma   HB               PCR-RFLP          108    125          27    260   100          128   32    260   0.37   0.359   10
  Peng \[[@R63]\]             2016   HCC            PB               PCR-RFLP          57     81           35    173   79           81    22    182   0.34   0.860   10
  Ma \[[@R91]\]               2016   Gastric        HB               PCR-RFLP          67     63           17    147   71           67    12    150   0.30   0.486   8

MAF: minor allele frequency; HWE: Hardy-Weinberg equilibrium; HB: hospital based; PB: population based; NA: not applicable; HCC: hepatocellular carcinoma; NPC: nasopharyngeal carcinoma; EHBD: extrahepatic bile duct; AV: ampulla of vater; HN: head and neck; NTCL: NK/T-cell lymphoma; AML: acute myeloid leukemia; NHL: non-Hodgkin's lymphoma; RCC: renal cell carcinoma; PCR-RFLP: polymorphism chain reaction restriction fragment length polymorphism; PCR-SSP: polymerase chain reaction sequence-specific primer; AS-PCR: allele-specific polymorphism chain reaction; PCR-LDR: polymorphism chain reaction-ligase detection reaction; SBE: single base extension; MALDI-TOF MS: matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry.

^a^ Heneghan \[[@R41]\], Shih \[[@R42]\], Hsing \[[@R44]\] (extrahepatic bile duct cancer and ampulla of vater cancer), Xiao \[[@R47]\], He \[[@R52]\], Chang \[[@R53]\], Cheng \[[@R57]\], Hsu \[[@R59]\] and Cai \[[@R62]\] were only calculated for the heterozygous model, dominant model and allele comparison for the *IL-10* -1082A/G polymorphism, and the number of GG genotype was zero.

^b^ Bai \[[@R44]\], Hao \[[@R46]\] and Niu \[[@R50]\] were only calculated for the dominant model.

For the studies assessing three polymorphisms (-1082A/G, -819T/C and -592A/C) \[[@R32], [@R37]\], two (-1082A/G and -592A/C) \[[@R31]\], only one such as -1082A/G \[[@R29], [@R30], [@R33]-[@R35], [@R38]\] or -819T/C \[[@R36], [@R39]\] polymorphism and cancer risk but no other *IL-10* gene polymorphisms, the genotypes distribution in the controls were deviated from HWE, thus, these studies were excluded in the final analysis. Sixteen studies were also deviated from HWE, but the genotypes distribution in the controls of eight studies \[[@R18], [@R64]-[@R67], [@R70], [@R73], [@R76]\] were consistent with that expected from the HWE for both -819T/C and -592A/C polymorphisms, five \[[@R81], [@R84], [@R86], [@R87], [@R90]\] for the -592A/C polymorphism and three \[[@R41], [@R48], [@R54]\] for the -1082A/G polymorphism, thus, these studies were included in the final analysis. For those studies \[[@R18], [@R45], [@R65]\] with the same control subjects, the control numbers were calculated once in the total number. Overall, 26 studies with 4,901 cases and 6,426 controls for the -1082A/G polymorphism, 33 studies with 6,717 cases and 8,550 controls for the -819T/C polymorphism, and 42 studies with 9,934 cases and 13,169 controls for the -592A/C polymorphism were considered in this meta-analysis. Sample sizes for cases of the included studies ranged from 43 to 400 for the -1082A/G polymorphism, 43 to 589 for the -819T/C polymorphism, and 70 to 720 for the -592A/C polymorphism.

As regards the -1082A/G polymorphism, five studies focused on gastric cancer \[[@R40], [@R44], [@R47], [@R52], [@R56]\], three on hepatocellular carcinoma \[[@R41], [@R49], [@R63]\], two studies for each of the following cancer types, such as lung cancer \[[@R42], [@R46]\], cervical cancer \[[@R51], [@R61]\] and esophageal cancer \[[@R55], [@R60]\], and the other cancer types with one study per each cancer type. As regards the -819T/C polymorphism, 10 studies focused on gastric cancer \[[@R18], [@R47], [@R52], [@R64], [@R65], [@R68], [@R70], [@R72], [@R73], [@R77]\], four on hepatocellular carcinoma \[[@R18], [@R49], [@R63], [@R69]\], three on esophageal cancer \[[@R18], [@R60], [@R65]\], two studies for each of the following cancer types, such as lung cancer \[[@R42], [@R75]\], oral cancer \[[@R59], [@R66]\] and acute myeloid leukemia \[[@R58], [@R74]\], and the other cancer types with one study per each cancer type. As regards the -592A/C polymorphism, 11 studies focused on gastric cancer \[[@R18], [@R47], [@R52], [@R56], [@R64], [@R65], [@R70], [@R73], [@R87], [@R89], [@R91]\], five on hepatocellular carcinoma \[[@R18], [@R63], [@R69], [@R78], [@R85]\], four studies for each of the following cancer types, such as lung cancer \[[@R42], [@R75], [@R80], [@R86]\] and esophageal cancer \[[@R18], [@R60], [@R65], [@R83]\], three on cervical cancer \[[@R61], [@R79], [@R81]\], two studies for each of the following cancer types, such as nasopharyngeal carcinoma \[[@R43], [@R84]\], oral cancer \[[@R59], [@R66]\], acute myeloid leukemia \[[@R58], [@R74]\] and colorectal cancer \[[@R62], [@R88]\], and the other cancer types with one study per each cancer type. Among all studies, 18 were hospital-based and eight were population-based associated to the -1082A/G polymorphism, 23 were hospital-based and 10 were population-based associated to the -819T/C polymorphism, 31 were hospital-based and 11 were population-based associated to the -592A/C polymorphism. Furthermore, 18 studies were rated as low quality (quality score ≤ 9) and eight were considered as high quality (quality score \> 9) for the -1082A/G polymorphism, 16 were low quality and 17 were high quality studies for the -819T/C polymorphism, 21 were low quality and 21 were high quality studies for the -592A/C polymorphism. Controls were matched for age and sex in most studies, and cases were mostly histologically confirmed.

Meta-analysis results {#s2_2}
---------------------

The main results regarding the association between *IL-10* -1082A/G polymorphism and cancer risk are shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. A significant association was found between *IL-10* -1082A/G polymorphism and overall cancer risk \[dominant: odds ratio (OR) = 1.32, 95% confidence interval (CI) = 1.04-1.67, *P* \< 0.001\]. In the subgroup analysis, a statistically significant association was found for hepatocellular carcinoma (heterozygous: OR = 1.40, 95% CI = 1.01-1.94, *P* = 0.433; dominant: OR = 1.43, 95% CI = 1.04-1.95, *P* = 0.497 and allele comparison: OR = 1.35, 95% CI = 1.04-1.75, *P* = 0.480) and low quality studies (heterozygous: OR = 1.42, 95% CI = 1.05-1.91, *P* \< 0.001; dominant: OR = 1.56, 95% CI = 1.17-2.08, *P* \< 0.001 and allele comparison: OR = 1.43, 95% CI = 1.08-1.88, *P* \< 0.001).

###### Meta-analysis of the association between IL-10 polymorphisms and cancer risk

  Variables           No. of studies   Sample size (case/controls)   Homozygous             Heterozygous   Recessive              Dominant   Allele comparison                                                                        
  ------------------- ---------------- ----------------------------- ---------------------- -------------- ---------------------- ---------- ---------------------- --------- ---------------------- --------- ---------------------- ---------
  -1082A/G                                                           GG *vs.* AA                           AG *vs.* AA                       GG *vs.*(AA+AG)                  (AG+GG) *vs.* AA                 G *vs.*A               
  All                 26               4,901/6,426                   1.21 (0.80-1.85)       0.025          1.22 (0.97-1.54)       \<0.001    1.12 (0.84-1.48)       0.242     **1.32 (1.04-1.67)**   \<0.001   1.22 (0.99-1.51)       \<0.001
  Cancer type                                                                                                                                                                                                                         
  Gastric             5                985/1,511                     1.38 (0.37-5.20)       0.930          1.70 (0.79-3.66)       \<0.001    1.37 (0.36-5.13)       0.953     1.97 (0.97-3.99)       \<0.001   1.72 (0.79-3.71)       \<0.001
  HCC                 3                441/466                       1.56 (0.77-3.18)       0.950          **1.40 (1.01-1.94)**   0.433      1.45 (0.73-2.90)       0.978     **1.43 (1.04-1.95)**   0.497     **1.35 (1.04-1.75)**   0.480
  Lung ^a^            2                197/257                       NA                     NA             NA                     NA         NA                     NA        3.24 (0.84-12.54)      0.047     NA                     NA
  Cervical            2                351/365                       1.45 (0.87-2.40)       0.792          1.31 (0.96-1.79)       0.371      1.26 (0.78-2.04)       0.991     1.33 (0.99-1.79)       0.386     1.24 (0.99-1.55)       0.490
  Esophageal          2                364/611                       0.88 (0.14-5.40)       0.099          0.88 (0.36-2.14)       0.041      0.94 (0.29-3.01)       0.205     0.87 (0.29-2.56)       0.009     1.00 (0.44-2.26)       0.015
  Others              12               2,563/3,216                   1.30 (0.59-2.85)       0.168          0.96 (0.74-1.25)       0.002      1.30 (0.68-2.46)       0.280     1.05 (0.78-1.41)       \<0.001   0.97 (0.74-1.27)       \<0.001
  Source of control                                                                                                                                                                                                                   
  PB                  8                1,025/1,398                   1.42 (0.87-2.33)       0.454          1.13 (0.84-1.53)       0.114      1.25 (0.78-2.01)       0.538     1.29 (0.92-1.80)       0.013     1.07 (0.82-1.41)       0.078
  HB                  18               3,876/5,028                   1.20 (0.69-2.09)       0.018          1.25 (0.93-1.68)       \<0.001    1.13 (0.78-1.64)       0.183     1.33 (0.98-1.80)       \<0.001   1.27 (0.97-1.68)       \<0.001
  Score                                                                                                                                                                                                                               
  Low                 18               3,365/4,373                   1.29 (0.78-2.12)       0.012          **1.42 (1.05-1.91)**   \<0.001    1.16 (0.83-1.63)       0.160     **1.56 (1.17-2.08)**   \<0.001   **1.43 (1.08-1.88)**   \<0.001
  High                8                1,536/2,053                   1.13 (0.52-2.48)       0.349          0.89 (0.68-1.17)       0.073      1.15 (0.57-2.31)       0.417     0.88 (0.67-1.67)       0.059     0.88 (0.68-1.14)       0.047
  -819T/C                                                            CC *vs.*TT                            CT *vs.*TT                        CC *vs.*(TT+CT)                  (CT+CC) *vs.*TT                  C *vs.*T               
  All                 33               6,717/8,550                   **1.19 (1.00-1.41)**   \<0.001        1.04 (0.93-1.16)       \<0.001    **1.17 (1.00-1.36)**   \<0.001   1.08 (0.97-1.20)       \<0.001   **1.08 (1.00-1.18)**   \<0.001
  Cancer type                                                                                                                                                                                                                         
  Gastric             10               1,772/2,142                   1.08 (0.79-1.47)       0.021          1.15 (0.95-1.38)       0.046      1.01 (0.81-1.27)       0.196     1.14 (0.93-1.40)       0.007     1.08 (0.92-1.27)       0.002
  HCC                 4                1,118/1,344                   1.14 (0.86-1.51)       0.744          0.96 (0.78-1.19)       0.396      1.04 (0.86-1.26)       0.668     1.00 (0.82-1.22)       0.412     1.01 (0.90-1.15)       0.549
  Esophageal          3                558/873                       1.23 (0.90-1.67)       0.940          1.02 (0.82-1.27)       0.741      1.21 (0.91-1.61)       0.966     1.07 (0.87-1.31)       0.763     1.09 (0.94-1.27)       0.852
  Lung                2                484/541                       **2.66 (1.84-3.84)**   0.569          1.18 (0.90-1.56)       0.560      **2.40 (1.71-3.37)**   0.399     **1.49 (1.16-1.92)**   0.633     **1.59 (1.33-1.91)**   0.920
  Oral                2                425/412                       **1.58 (1.01-2.46)**   0.464          1.77 (0.58-5.37)       0.001      1.35 (0.89-2.06)       0.583     1.80 (0.67-4.82)       0.002     1.38 (0.94-2.02)       0.080
  AML                 2                282/465                       0.87 (0.22-3.48)       0.006          0.80 (0.32-2.01)       0.007      0.98 (0.38-2.53)       0.046     0.82 (0.29-2.34)       0.001     0.88 (0.38-2.03)       \<0.001
  Others              10               2,078/2,773                   1.08 (0.76-1.53)       \<0.001        0.91 (0.76-1.09)       0.047      1.14 (0.79-1.65)       \<0.001   0.95 (0.82-1.11)       0.117     1.10 (0.87-1.18)       0.001
  Source of control                                                                                                                                                                                                                   
  PB                  10               1,502/1,872                   1.24 (0.93-1.65)       0.035          0.96 (0.79-1.16)       0.035      1.31 (0.92-1.86)       \<0.001   1.01 (0.88-1.16)       0.248     1.08 (0.95-1.24)       0.031
  HB                  23               5,215/6,678                   1.17 (0.94-1.44)       \<0.001        1.08 (0.95-1.22)       0.001      1.12 (0.95-1.33)       \<0.001   1.10 (0.96-1.27)       \<0.001   1.08 (0.97-1.20)       \<0.001
  Score                                                                                                                                                                                                                               
  Low                 16               3,039/4,160                   1.21 (0.89-1.64)       \<0.001        1.07 (0.89-1.29)       \<0.001    1.18 (0.92-1.51)       \<0.001   1.11 (0.91-1.36)       \<0.001   1.10 (0.94-1.29)       \<0.001
  High                17               3,678/4,390                   1.17 (0.98-1.39)       0.075          1.01 (0.89-1.13)       0.097      1.16 (0.95-1.42)       0.001     1.03 (0.94-1.12)       0.409     1.05 (0.97-1.14)       0.089
  -592A/C                                                            CC *vs.*AA                            AC *vs.*AA                        CC *vs.*(AA+AC)                  (AC+CC) *vs.*AA                  C *vs.*A               
  All                 42               9,934/13,169                  **1.13 (1.00-1.28)**   0.001          1.04 (0.96-1.13)       0.001      1.10 (0.99-1.21)       0.035     1.06 (0.97-1.15)       \<0.001   1.05 (0.99-1.12)       \<0.001
  Cancer type                                                                                                                                                                                                                         
  Gastric             11               2,324/2,775                   1.18 (0.96-1.44)       0.289          1.08 (0.94-1.23)       0.200      1.11 (0.94-1.32)       0.562     1.10 (0.95-1.27)       0.093     1.08 (0.97-1.21)       0.080
  HCC                 5                1,859/2,109                   1.20 (0.82-1.75)       0.032          1.09 (0.94-1.27)       0.650      1.10 (0.80-1.50)       0.039     1.09 (0.94-1.27)       0.373     1.08 (0.93-1.24)       0.094
  Esophageal          4                900/1,243                     1.18 (0.90-1.54)       0.637          1.13 (0.93-1.36)       0.399      1.11 (0.88-1.39)       0.498     1.15 (0.96-1.37)       0.582     1.10 (0.97-1.25)       0.702
  Lung                4                958/1,377                     **1.64 (1.19-2.24)**   0.301          1.17 (0.94-1.45)       0.285      **1.52 (1.20-1.93)**   0.402     **1.27 (1.01-1.60)**   0.198     **1.27 (1.06-1.52)**   0.149
  Cervical            3                338/388                       0.89 (0.35-2.24)       0.031          0.91 (0.67-1.25)       0.431      0.94 (0.41-2.19)       0.042     0.89 (0.60-1.32)       0.174     0.91 (0.60-1.38)       0.034
  NPC                 2                374/732                       1.19 (0.62-2.31)       0.116          0.95 (0.72-1.25)       0.697      1.22 (0.66-2.25)       0.125     0.99 (0.77-1.29)       0.346     1.05 (0.78-1.42)       0.129
  Oral                2                425/412                       **1.58 (1.01-2.46)**   0.464          1.77 (0.58-5.37)       0.001      1.35 (0.89-2.06)       0.583     1.80 (0.67-4.82)       0.002     1.38 (0.94-2.02)       0.080
  AML                 2                282/465                       0.84 (0.23-3.05)       0.011          0.79 (0.33-1.90)       0.010      0.95 (0.40-2.27)       0.064     0.80 (0.30-2.16)       0.002     0.86 (0.39-1.88)       0.001
  Colorectal          2                673/673                       **0.58 (0.40-0.85)**   0.694          **0.66 (0.53-0.83)**   0.882      0.70 (0.49-1.01)       0.599     **0.65 (0.52-0.80)**   0.994     **0.72 (0.61-0.85)**   0.750
  Others              7                1,801/2,995                   0.98 (0.77-1.24)       0.313          1.01 (0.86-1.17)       0.246      0.98 (0.80-1.21)       0.437     1.00 (0.86-1.16)       0.185     0.99 (0.88-1.11)       0.187
  Source of control                                                                                                                                                                                                                   
  PB                  11               2,203/2,780                   1.08 (0.82-1.43)       0.011          0.96 (0.82-1.13)       0.056      1.08 (0.89-1.33)       0.117     0.99 (0.82-1.18)       0.004     1.01 (0.87-1.16)       0.001
  HB                  31               7,731/10,389                  1.14 (0.99-1.31)       0.009          1.07 (0.97-1.17)       0.004      1.10 (0.98-1.24)       0.054     1.09 (0.99-1.20)       \<0.001   **1.07 (1.00-1.15)**   \<0.001
  Score                                                                                                                                                                                                                               
  Low                 21               4,240/6,041                   **1.23 (1.02-1.49)**   0.012          1.03 (0.90-1.19)       \<0.001    **1.21 (1.05-1.40)**   0.193     1.08 (0.93-1.25)       \<0.001   1.09 (0.98-1.21)       \<0.001
  High                21               5,694/7,128                   1.05 (0.89-1.23)       0.023          1.05 (0.96-1.15)       0.161      1.02 (0.89-1.16)       0.100     1.05 (0.95-1.15)       0.033     1.03 (0.95-1.11)       0.007

Het: heterogeneity; NA: not applicable; HCC: hepatocellular carcinoma; NPC: nasopharyngeal carcinoma; AML: acute myeloid leukemia; PB: population based; HB: hospital based.

^a^ Lung cancer was only calculated for the dominant model.

![Forest plot for overall cancer risk associated with the IL-10 -1082A/G polymorphism by a dominant model\
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The overall results regarding the association between *IL-10* -819T/C polymorphism and cancer risk are shown in Table [2](#T2){ref-type="table"}. A significant association was found between *IL-10* -819T/C polymorphism and overall cancer risk (homozygous: OR = 1.19, 95% CI = 1.00-1.41, *P* \< 0.001; recessive: OR = 1.17, 95% CI = 1.00-1.36, *P* \< 0.001 and allele comparison: OR = 1.08, 95% CI = 1.00-1.18, *P* \< 0.001). In the subgroup analysis, a statistically significant association was found for lung cancer (homozygous: OR = 2.66, 95% CI = 1.84-3.84, *P* = 0.569; recessive: OR = 2.40, 95% CI = 1.71-3.37, *P* = 0.399; dominant: OR = 1.49, 95% CI = 1.16-1.92, *P* = 0.633 and allele comparison: OR = 1.59, 95% CI = 1.33-1.91, *P* = 0.920) and oral cancer (homozygous: OR = 1.58, 95% CI = 1.01-2.46, *P* = 0.464).

The detailed results regarding the association between *IL-10* -592A/C polymorphism and cancer risk are shown in Table [2](#T2){ref-type="table"}. A significant association was found between *IL-10* -592A/C polymorphism and increased overall cancer risk (homozygous: OR = 1.13, 95% CI = 1.00-1.28, *P* = 0.001). In the subgroup analysis, a statistically significant increased risk was found for lung cancer (homozygous: OR = 1.64, 95% CI = 1.19-2.24, *P* = 0.301; recessive: OR = 1.52, 95% CI = 1.20-1.93, *P* = 0.402; dominant: OR = 1.27, 95% CI = 1.01-1.60, *P* = 0.198 and allele comparison: OR = 1.27, 95% CI = 1.06-1.52, *P* = 0.149), oral cancer (homozygous: OR = 1.58, 95% CI = 1.01-2.46, *P* = 0.464), hospital-based studies (allele comparison: OR = 1.07, 95% CI = 1.00-1.15, *P* \< 0.001) and low quality studies (homozygous: OR = 1.23, 95% CI = 1.02-1.49, *P* = 0.012 and recessive: OR = 1.21, 95% CI = 1.05-1.40, *P* = 0.193). In contrast, a significantly decreased risk was observed for colorectal cancer (homozygous: OR = 0.58, 95% CI = 0.40-0.85, *P* = 0.694; heterozygous: OR = 0.66, 95% CI = 0.53-0.83, *P* = 0.882; dominant: OR = 0.65, 95% CI = 0.52-0.80, *P* = 0.994 and allele comparison: OR = 0.72, 95% CI = 0.61-0.85, *P* = 0.750).

Heterogeneity and sensitivity analysis {#s2_3}
--------------------------------------

Substantial heterogeneities were found among all studies regarding *IL-10* -1082A/G polymorphism and overall cancer risk (homozygous: *P* = 0.025; heterozygous: *P* \< 0.001; dominant: *P* \< 0.001 and allele comparison: *P* \< 0.001), but not under the recessive model (*P* = 0.242) (Table [2](#T2){ref-type="table"}). Considerable heterogeneities were also observed for the -819T/C (all *P* \< 0.001) and -592A/C (homozygous: *P* = 0.001; heterozygous: *P* = 0.001; recessive: *P* = 0.035; dominant: *P* \< 0.001 and allele comparison: *P* \< 0.001) polymorphisms. Therefore, the random-effect model was used to generate wider CIs. Sensitivity analysis was conducted and the results indicated that each individual study did not influence the pooled ORs obviously (data not shown).

Publication bias {#s2_4}
----------------

The funnel plot was symmetric for the -1082A/G (Figure [3](#F3){ref-type="fig"}), -819T/C and -592A/C polymorphisms, indicating no presence of publication bias, which was further supported by the Egger's test for the -1082A/G polymorphism (homozygous: *P* = 0.428; heterozygous: *P* = 0.395; recessive: *P* = 0.168; dominant: *P* = 0.223 and allele comparison: *P* = 0.179), -819T/C polymorphism (homozygous: *P* = 0.589; heterozygous: *P* = 0.777; recessive: *P* = 0.616; dominant: *P* = 0.797 and allele comparison: *P* = 0.576), and -592A/C polymorphism (homozygous: *P* = 0.727; heterozygous: *P* = 0.763; recessive: *P* = 0.748; dominant: *P* = 0.474 and allele comparison: *P* = 0.677).

![Begg's funnel plot for the *IL-10* -1082A/G polymorphism and overall cancer risk by a dominant model](oncotarget-08-62382-g003){#F3}

False-positive report probability (FPRP) test analysis {#s2_5}
------------------------------------------------------

The significant findings were assessed using the FPRP test and the results are shown in Table [3](#T3){ref-type="table"}. With a prior probability of 0.1, assuming that the OR for a specific genotype was 0.67/1.50 (protection/risk), with statistical power of 0.857, the FPRP value was 0.179 for the -1082A/G polymorphism and cancer risk under the dominant model, and a positive association was also found for low quality studies (dominant: FPRP = 0.053 and allele comparison: FPRP = 0.129). As regards the -819T/C polymorphism, a positive association was found for lung cancer (homozygous: FPRP = 0.001; recessive: FPRP = 0.001; dominant: FPRP = 0.034 and allele comparison: FPRP \< 0.001). As regards the -592A/C polymorphism, noteworthy findings were observed for lung cancer (homozygous: FPRP = 0.055; recessive: FPRP = 0.011 and allele comparison: FPRP = 0.078), colorectal cancer (homozygous: FPRP = 0.165; heterozygous: FPRP = 0.007; dominant: FPRP = 0.001 and allele comparison: FPRP = 0.001) and low quality studies (recessive: FPRP = 0.086). However, greater FPRP values were observed for other significant findings, which need validation in further studies.

###### False-positive report probability values for associations between cancer risk and *IL-10* polymorphisms

  Genotype                         Crude OR (95% CI)   *P*-valuea   Statistical powerb   Prior probability                                           
  -------------------------------- ------------------- ------------ -------------------- ------------------- ------------- ------------- ----------- -----------
  -1082A/G                                                                                                                                           
   All                                                                                                                                               
  Dominant                         1.32 (1.04-1.67)    0.021        0.857                **0.068**           **0.179**     0.705         0.960       0.996
   Cancer type-HCC                                                                                                                                   
  Heterozygous                     1.40 (1.01-1.94)    0.043        0.661                **0.164**           0.371         0.866         0.985       0.998
  Dominant                         1.43 (1.04-1.95)    0.024        0.619                **0.103**           0.257         0.792         0.975       0.997
  Allele comparison                1.35 (1.04-1.75)    0.023        0.787                **0.082**           0.211         0.747         0.967       0.997
   Quality score-low                                                                                                                                 
  Heterozygous                     1.42 (1.05-1.91)    0.020        0.641                **0.087**           0.223         0.759         0.970       0.997
  Dominant                         1.56 (1.17-2.08)    0.002        0.395                **0.018**           **0.053**     0.380         0.861       0.984
  Allele comparison                1.43 (1.08-1.88)    0.010        0.634                **0.047**           **0.129**     0.619         0.942       0.994
   -819T/C                                                                                                                                           
   All                                                                                                                                               
  Homozygous                       1.19 (1.00-1.41)    0.044        0.996                **0.118**           0.286         0.815         0.978       0.998
  Recessive                        1.17 (1.00-1.36)    0.041        0.999                **0.109**           0.269         0.802         0.976       0.998
  Allele comparison                1.08 (1.00-1.18)    0.088        1.000                0.210               0.443         0.898         0.989       0.999
   Cancer type-lung cancer                                                                                                                           
  Homozygous                       2.66 (1.84-3.84)    \<0.001      0.001                **\<0.001**         **0.001**     **0.015**     **0.137**   0.613
  Recessive                        2.40 (1.71-3.37)    \<0.001      0.003                **\<0.001**         **0.001**     **0.013**     **0.114**   0.564
  Dominant                         1.49 (1.16-1.92)    0.002        0.521                **0.012**           **0.034**     0.281         0.797       0.975
  Allele comparison                1.59 (1.33-1.91)    \<0.001      0.267                **\<0.001**         **\<0.001**   **\<0.001**   **0.003**   **0.026**
   Cancer type-oral cancer                                                                                                                           
  Homozygous                       1.58 (1.01-2.46)    0.043        0.409                0.239               0.485         0.912         0.991       0.999
   -592A/C                                                                                                                                           
   All                                                                                                                                               
  Homozygous                       1.13 (1.00-1.28)    0.055        1.000                **0.141**           0.330         0.844         0.982       0.998
   Cancer type-lung cancer                                                                                                                           
  Homozygous                       1.64 (1.19-2.24)    0.002        0.287                **0.019**           **0.055**     0.392         0.867       0.985
  Recessive                        1.52 (1.20-1.93)    0.001        0.457                **0.004**           **0.011**     **0.113**     0.563       0.928
  Dominant                         1.27 (1.01-1.60)    0.043        0.921                **0.122**           0.294         0.821         0.979       0.998
  Allele comparison                1.27 (1.06-1.52)    0.009        0.965                **0.028**           **0.078**     0.484         0.904       0.990
   Cancer type-oral cancer                                                                                                                           
  Homozygous                       1.58 (1.01-2.46)    0.043        0.409                0.239               0.485         0.912         0.991       0.999
   Cancer type-colorectal cancer                                                                                                                     
  Homozygous                       0.58 (0.40-0.85)    0.005        0.238                **0.062**           **0.165**     0.685         0.956       0.995
  Heterozygous                     0.66 (0.53-0.83)    \<0.001      0.466                **0.002**           **0.007**     **0.075**     0.449       0.891
  Dominant                         0.65 (0.52-0.80)    \<0.001      0.406                **\<0.001**         **0.001**     **0.012**     0.105       0.541
  Allele comparison                0.72 (0.61-0.85)    \<0.001      0.818                **\<0.001**         **0.001**     **0.013**     0.113       0.562
   Control source-HB                                                                                                                                 
  Allele comparison                1.07 (1.00-1.15)    0.066        1.000                **0.165**           0.372         0.867         0.985       0.998
   Quality score-low                                                                                                                                 
  Homozygous                       1.23 (1.02-1.49)    0.034        0.979                **0.095**           0.240         0.777         0.972       0.997
  Recessive                        1.21 (1.05-1.40)    0.010        0.998                **0.030**           **0.086**     0.508         0.913       0.991

HCC: hepatocellular carcinoma; HB: hospital based.

^a^Chi-square test was used to calculate the genotype frequency distributions.

^b^Statistical power was calculated using the number of observations in the subgroup and the OR and *P* values in this table.

DISCUSSION {#s3}
==========

In this meta-analysis, we comprehensively investigated the associations between three promoter variants (-1082A/G, -819T/C and -592A/C) in *IL-10* gene and cancer risk in the Chinese population through 53 articles. The results revealed that all the three *IL-10* gene polymorphisms we considered were associated with an increased overall cancer risk. Stratification analysis showed that the association between the -1082A/G polymorphism and cancer risk was more evident for hepatocellular carcinoma and low quality studies, the association between the -819T/C polymorphism and cancer risk was more obvious for lung cancer and oral cancer. However, the -592A/C polymorphism showed a statistically significant increased risk for lung cancer, oral cancer, hospital-based studies and low quality studies, but a decreased risk for colorectal cancer. To our knowledge, this is so far the first meta-analysis that has assessed multiple promoter polymorphisms in *IL-10* gene with cancer risk in the Chinese population.

Three meta-analyses including international studies have investigated the association of *IL-10* -1082A/G, -819T/C and -592A/C polymorphisms with overall cancer susceptibility. The study carried out by Wang *et al.* \[[@R92]\] analyzed *IL-10* -1082A/G polymorphism, consisting 61 international studies with a total of 14,499 cases and 16,967 controls, in which no significant association was found between this polymorphism and overall cancer risk. Another meta-analysis \[[@R93]\] including 15,942 cases and 22,336 controls investigated *IL-10* -819C/T polymorphism and cancer risk, without finding any significant association between this polymorphism and overall cancer risk. The study carried out by Ding *et al.* \[[@R94]\] considered *IL-10* -592C/A polymorphism, in which a decreased risk of overall cancer was found with the AA genotype. Other meta-analyses with international studies have assessed the association between polymorphisms in *IL-10* gene and susceptibility to some types of cancer. For example, two studies \[[@R95], [@R96]\] revealed no significant association between *IL-10* -1082A/G, -819T/C and -592A/C polymorphisms with non-Hodgkin lymphoma susceptibility. Some of the significant associations found in the previous studies were not validated in our meta-analysis, for example, *IL-10* -1082A/G polymorphism was associated with an increased lung cancer risk \[[@R92]\]. We also found some significant associations that were not observed in previous analyses. For instance, we found that *IL-10* -592A/C polymorphism was associated with a decreased colorectal cancer risk. The discrepancy occurred because our analysis was carried out only in the Chinese population, suggesting that the polymorphisms on cancer risk might vary among different study subjects' ethnicity or lifestyle factors.

To make our significant findings more noteworthy, FPRP analysis was performed. Interestingly, FPRP test results revealed that only the association between *IL-10* -1082A/G polymorphism and overall cancer risk remained significant at the prior probability level of 0.1. In the subgroup analysis, only the low quality studies, lung cancer and colorectal cancer remained significant. Other findings were false-positive, which might be due to the limited sample size.

Our present meta-analysis has some highlights. First, it identified the significant association between *IL-10* -1082A/G, -819T/C and -592A/C polymorphisms and an increased overall cancer risk in the Chinese population. Second, the quality of each included study was evaluated by the quality score criteria. Third, no publication bias was detected in the study, indicating the robustness of the results. Finally, the significant findings were further validated using the FPRP test, making the results more authentic. However, some possible limitations should be considered. First, the total sample size in each individual study was less than 1000 in all but four studies \[[@R69], [@R82], [@R85], [@R86]\], which might reflect a difficulty to evaluate the real association. Second, our results were based on unadjusted estimates, which might cause confounding bias. Third, in the subgroup analysis by cancer type, only two studies were included for some types of cancer, which might affect the detection of the real association. Finally, the potential gene-gene, and gene-environment interactions were not assessed due to the lack of information in the original studies.

In conclusion, this meta-analysis suggested an association between *IL-10* gene polymorphisms and cancer risk in the Chinese population, especially for lung cancer, colorectal cancer and low quality studies. Well-designed studies with large sample size are required to verify our findings.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

A systematic literature search was conducted in PubMed, Embase, CNKI and Wanfang database using the following MeSH terms and their synonyms: ("*interleukin-10*" or "*interleukin 10*" or "*IL-10*" or "*IL 10*") AND ("polymorphism, single nucleotide" \[MeSH\] or "SNP" or "single nucleotide polymorphism" or "polymorphism" or "variant" or "variation") AND ("neoplasms" \[MeSH\] or "neoplasia" or "neoplasm" or "tumor" or "malignancy" or "cancer"), up to 19 January, 2017. In addition, review articles and references of the selected articles were manually searched to identify additional relevant articles. Only the most recent publications or the ones with most participants were included in the final meta-analysis in cases of overlapping data.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The inclusion criteria were as follows: (1) studies investigating the association between *IL-10* -1082A/G, -819T/C and -592A/C polymorphisms with cancer risk in Chinese populations; (2) case-control studies; (3) studies providing sufficient data for calculation of ORs and 95% CIs. Studies were excluded if any of the following aspects existed: (1) not a case-control study; (2) duplicate publications; (3) studies without available genotype data; (4) review articles, meta-analyses, conference abstracts or editorial articles; and (5) genotype frequencies in the controls departure from HWE.

Data extraction {#s4_3}
---------------

Two investigators independently extracted the relevant data from all included studies based on the inclusion criteria listed above. Disagreement was resolved by discussion with a third investigator. The following information was extracted from each included study: first author's surname, publication year, cancer type, control source (hospital-based or population-based), genotyping methods, and number of cases and controls with different genotypes.

Quality assessment {#s4_4}
------------------

Two independent investigators assessed the qualities of all included studies according to the criteria from a previous meta-analysis \[[@R97]\]. Quality scores of studies ranged from 0 (lowest) to 15 (highest), and the studies with scores \> 9 were considered of high quality.

Statistical analysis {#s4_5}
--------------------

The strength of association between *IL-10* -1082A/G, -819T/C and -592A/C polymorphisms and cancer risk was assessed by calculating the ORs and the corresponding 95% CIs. The pooled ORs were calculated for the homozygous model, heterozygous model, recessive model, dominant model and an allele comparison. The between-study heterogeneity was quantified by chi-square based Q test and the fixed-effects model (the Mantel-Haenszel method) \[[@R98]\] was used when no significant heterogeneity was observed (*P* \> 0.1); otherwise, the random-effects model (the DerSimonian and Laird method) \[[@R99]\] was adopted. Subgroup analysis was performed by cancer type (if one cancer type contained less than two studies, it was merged into the "other cancers" group), control source (hospital-based studies and population-based studies), and quality scores (≤ 9 and \> 9). Sensitivity analysis was performed to assess results stability. Publication bias was examined using Begg's funnel plot and Egger's linear regression test.

The FPRP was calculated to examine the significant associations found in the present meta-analysis. FPRP was calculated with 0.2 as a FPRP threshold and a prior probability of 0.1 was assigned to detect an OR of 0.67/1.50 (protective/risk effects) for an association with the genotypes under investigation \[[@R100]\]. FPRP values below threshold 0.2 were considered as noteworthy associations. All the statistical tests were performed using STATA version 12.0 (Stata Corporation, College Station, TX). All the *P* values were two-sided, and *P* \< 0.05 were considered statistically significant.
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